Specifically, we reviewed the literature to first examine the modalities in which such treatments were delivered (computer, smartphone, watch and other), types of behavioral intervention delivered (CBT, biofeedback, relaxation, other), the headache type being treated, duration of the treatment, adherence, and outcomes obtained by the trials.
Multiple comparisons could be made, including condition treated, duration of study, comparator drug, and dose.
Rates of hypoglycaemia varied and were higher in some trials than others, varying by trial population (T1DM or T2DM, insulin naïve or insulin treated), duration of diabetes and levels of glycaemic control at baseline as well as the treatment regimen (basal only or basal bolus therapy).
The active and placebo gels were also compared during the blinded phase for rate of response of all tumours treated; duration of and time to response of the target tumour and all tumours treated; time to progression of the target tumour and all tumours treated; and quality of life, as measured by the FACT-H&N (Cella, 1993) administered at weeks 1 and 4 and the end of follow-up.
Because lung cancer risk decreased with total employment duration, we can treat duration as a surrogate of time-varying health status.
To report indications, substance group, origin, self-rated improvement of conditions treated, tolerance, duration of use and perceived adverse drug reactions (ADRs).
In selected patients, these methods result in a reduction in the volumes treated and duration of radiation without a reduction in survival.
Based on veterinary directions, the farmer chose when to initiate treatment, how to treat, the duration of treatment and what dose to use.
The following sources (indicators) were used: Globocan2008 (incidence and mortality), various cancer registries (proportion cured, proportion treated and duration of disease), treatment guidelines (duration of treatment), specific burden of disease studies (sequelae and disability weights), alongside expert opinion.
The most robust data currently available in terms of the numbers of patients treated and duration of follow-up (for safety and efficacy) support the use of zoledronic acid (4 mg twice a year) to prevent CTIBL/AIBL in women receiving adjuvant endocrine therapy [ 42- 44].
No additional effect of mean baseline age, previous diabetes treatment that the DPP-4 inhibitor was added to, statistical evaluation of the trial (per protocol or intention-to-treat) and duration of treatment was found, with no significant coefficients or increase of variance explained by the model (<1%).
